Brief: Newron Pharmaceuticals: Xadago available in U.S. for Parkinson's disease patients
11/07/2017 12:30
July 11 (Reuters) - NEWRON PHARMACEUTICALS SPA NWRN.S :
* XADAGO(R) (SAFINAMIDE) NOW AVAILABLE IN U.S. FOR PARKINSON'S DISEASE PATIENTS
Source text for Eikon: ID:nTENflwu9a
Further company coverage: NWRN.S
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study